MX379371B - Composiciones. - Google Patents

Composiciones.

Info

Publication number
MX379371B
MX379371B MX2017006168A MX2017006168A MX379371B MX 379371 B MX379371 B MX 379371B MX 2017006168 A MX2017006168 A MX 2017006168A MX 2017006168 A MX2017006168 A MX 2017006168A MX 379371 B MX379371 B MX 379371B
Authority
MX
Mexico
Prior art keywords
hpc
wax
core
delayed release
coated tablet
Prior art date
Application number
MX2017006168A
Other languages
English (en)
Other versions
MX2017006168A (es
Inventor
Alexander Balfour Mullen
David Smith
Fiona Jane Macdougall
Howard Norman Ernest Stevens
Vivekanand Bhardwaj
Original Assignee
Drug Delivery Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Delivery Int Ltd filed Critical Drug Delivery Int Ltd
Publication of MX2017006168A publication Critical patent/MX2017006168A/es
Publication of MX379371B publication Critical patent/MX379371B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/288Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una tableta revestida en prensa para liberación retardada de un ingrediente activo que comprende: (a) un núcleo que comprende uno o más ingredientes activos, y; (b) una barrera de liberación retardada erosionable que circunda el núcleo y que comprende una cera y dos o más grados de LHPC, en donde la cera y L-HPC se proporcionan en una relación en peso de cera a L-HPC de 30%:70% a 70%:30%. La invención también se refiere a un método para hacer la tableta revestida en prensa.
MX2017006168A 2014-11-14 2015-11-16 Composiciones. MX379371B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1420306.1A GB201420306D0 (en) 2014-11-14 2014-11-14 Compositions
PCT/GB2015/053471 WO2016075495A1 (en) 2014-11-14 2015-11-16 Composition

Publications (2)

Publication Number Publication Date
MX2017006168A MX2017006168A (es) 2017-09-12
MX379371B true MX379371B (es) 2025-03-10

Family

ID=52248394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006168A MX379371B (es) 2014-11-14 2015-11-16 Composiciones.

Country Status (18)

Country Link
US (1) US10675247B2 (es)
EP (1) EP3217964B1 (es)
JP (1) JP6774103B2 (es)
KR (1) KR102253728B1 (es)
CN (1) CN106999438A (es)
AU (1) AU2015344838B2 (es)
CA (1) CA2967738C (es)
DK (1) DK3217964T3 (es)
ES (1) ES2755960T3 (es)
GB (1) GB201420306D0 (es)
HU (1) HUE047581T2 (es)
MX (1) MX379371B (es)
PL (1) PL3217964T3 (es)
PT (1) PT3217964T (es)
RU (1) RU2717574C2 (es)
SA (1) SA517381522B1 (es)
SI (1) SI3217964T1 (es)
WO (1) WO2016075495A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201420311D0 (en) * 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
CN111698983B (zh) * 2018-01-09 2022-10-18 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
WO2023214280A1 (en) * 2022-05-06 2023-11-09 Craft Health Pte Ltd System for controllable release in 3d-printed colon targeting (corr3ct) oral dosage form

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
JPS5839618A (ja) 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
WO1993019741A1 (en) * 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
JP3059004B2 (ja) * 1992-09-18 2000-07-04 ダイセル化学工業株式会社 アルカリ水溶液に対する溶解性の高い低置換度ヒドロキシプロピルセルロース及びその製造法
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5690959A (en) 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
ES2559766T3 (es) 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US6340478B1 (en) 1999-06-07 2002-01-22 Bio Dar Ltd. Microencapsulated and controlled-release herbal formulations
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
AU6589200A (en) 1999-09-10 2001-04-17 Ranbaxy Laboratories Limited Extended release formulation of etodolac
IN190974B (es) 1999-09-10 2003-09-06 Ranbaxy Lab Ltd
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
CA2398555C (en) 2000-01-27 2008-04-22 Tanabe Seiyaku Co., Ltd. Sustained release preparation and method for producing the same
JP4817562B2 (ja) 2001-09-26 2011-11-16 東和薬品株式会社 長時間持続型ニフエジピン有核錠
JP2003171277A (ja) * 2001-12-07 2003-06-17 Wyeth Lederle Japan Ltd 薬物放出時間制御型固形製剤
JP4790597B2 (ja) 2003-04-24 2011-10-12 ヤゴテック アーゲー 規定されたコア幾何学的配置を有する遅延放出錠
US20040241234A1 (en) 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
EP1689367A1 (en) 2003-10-21 2006-08-16 Actavis Group HF Pharmaceutical formulations containing quetiapine
EP1715856B1 (en) 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US20060008527A1 (en) 2004-07-09 2006-01-12 Yury Lagoviyer Controlled phase composition technology as an improved process for protection of drugs
WO2006035313A1 (en) 2004-09-29 2006-04-06 Aurobindo Pharma Ltd Solid unit dosage forms of 5-ht1 agonist
US20070129402A1 (en) 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20080248107A1 (en) 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
CN104161736A (zh) * 2006-06-01 2014-11-26 Msd消费保健品公司 包含去氧肾上腺素的缓释药物制剂
KR100812538B1 (ko) 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
CA2703365A1 (en) 2007-10-25 2009-04-30 Yuka Yamanouchi Nifedipine-containing press coated tablet and method of preparing the same
JP4329947B1 (ja) * 2009-01-20 2009-09-09 ライオン株式会社 内服用錠剤
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
CN103690545A (zh) 2013-11-27 2014-04-02 河南中帅医药科技股份有限公司 口服泼尼松择时释放制剂及其制备方法
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
GB201420300D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Tablet

Also Published As

Publication number Publication date
PT3217964T (pt) 2019-11-26
CN106999438A (zh) 2017-08-01
KR20170084282A (ko) 2017-07-19
US10675247B2 (en) 2020-06-09
RU2017116588A3 (es) 2019-06-18
CA2967738C (en) 2021-07-06
WO2016075495A1 (en) 2016-05-19
KR102253728B1 (ko) 2021-05-21
BR112017010070A2 (pt) 2018-01-02
SA517381522B1 (ar) 2021-04-06
JP2017534688A (ja) 2017-11-24
AU2015344838A1 (en) 2017-06-01
PL3217964T3 (pl) 2020-03-31
CA2967738A1 (en) 2016-05-19
US20170333355A1 (en) 2017-11-23
GB201420306D0 (en) 2014-12-31
DK3217964T3 (da) 2019-11-25
HUE047581T2 (hu) 2020-05-28
JP6774103B2 (ja) 2020-10-21
EP3217964B1 (en) 2019-09-04
HK1244432A1 (en) 2018-08-10
EP3217964A1 (en) 2017-09-20
ES2755960T3 (es) 2020-04-24
SI3217964T1 (sl) 2020-02-28
RU2717574C2 (ru) 2020-03-24
MX2017006168A (es) 2017-09-12
AU2015344838B2 (en) 2020-10-08
RU2017116588A (ru) 2018-12-14

Similar Documents

Publication Publication Date Title
PH12020550622A1 (en) Kras g12c inhibitors
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
EA201501024A1 (ru) Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
IL273300A (en) High dose valbenazine formulation and related preparations, methods and kits
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
PH12016501841A1 (en) Immunosuppressant formulation
ZA201807446B (en) Improved drug formulations
MY183068A (en) Pharmaceutical formulation comprising antibody
ECSP17018513A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
IN2014KO00357A (es)
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX379371B (es) Composiciones.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX376853B (es) Odorante osmanthus.
EP3144005A4 (en) Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof
MX391400B (es) Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.
PH12019500024A1 (en) Pharmaceutical compositions
MX2018005134A (es) Formulacion de factor viii (fviii).
GR20150100035A (el) Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
MX2019000977A (es) Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación.